C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 3980-3986

  Roger, Simon D ^a   Locatelli, Francesco ^b   Woitas, Rainer P ^c   Laville, Maurice ^d   Tobe, Sheldon W ^e   Provenzano, Robert ^f   Golper, Thomas A ^g   Ruangkanchanasetr, Prajej ^h   Lee, Ho Yung ⁱ   Wu, Kwan Dun ^j   Nowicki, Michal ^k   Ladanyi, Agnes ^l   Martínez Castelao, Alberto ^m   Beyer, Ulrich ⁿ   Dougherty, Frank C ⁿ  

^a GOSFORD HOSPITAL   (Australia)

^b A MANZONI HOSPITAL   (Italy)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITÉ DE LYON   (France)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h PHRAMONGKUTKLAO HOSPITAL   (Thailand)

ⁱ Yonsei University College of Medicine   (South Korea)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^k Department of Nephrology Hypertension and Kidney Transplantation   (Poland)

^l Peterfy Hospital   (Hungary)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

anaemia; C.E.R.A.; chronic kidney disease; darbepoetin alfa; haemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 82255194325     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr160     Document Type: Article

References (14)

1. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000 (Pubitemid 20034923)
2. Lefebvre P, Vekeman F, Sarokhan B et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006; 22: 1929-1937 (Pubitemid 44663398)
3. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-712
4. Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008; 81: 63-69 (Pubitemid 350124538)
5. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395 (Pubitemid 29501473)
6. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215
7. Kessler M, Mart́nez-Castelao A, Siamopoulos KC et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int 2009; 14: 233-239
8. Macdougall IC, Walker R, Provenzano R et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3: 337-347
9. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510 (Pubitemid 39361354)
10. Pannier A, Jordan P, Dougherty FC et al. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. Curr Med Res Opin 2007; 23: 3025-3032
11. Locatelli F, Mann JFE, Aldigier J-C et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010; 73: 94-103
12. Levin NW, Fishbane S, Valdés Cañedo F et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421 (Pubitemid 47576167)
13. Sulowicz W, Locatelli F, Ryckelynck J-P et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J AmSoc Nephrol 2007; 2: 637-646
14. Carrera F, Lok CE, de Francisco A et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25: 4009-4017